Comparative Pharmacology
Head-to-head clinical analysis: GLUCOPHAGE versus RIOMET ER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GLUCOPHAGE versus RIOMET ER.
GLUCOPHAGE vs RIOMET ER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Metformin primarily decreases hepatic glucose production (gluconeogenesis) and increases peripheral insulin sensitivity, reducing glucose absorption from the gastrointestinal tract. It activates AMP-activated protein kinase (AMPK), leading to inhibition of gluconeogenic enzymes.
Biguanide that decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.
500 mg orally once daily, titrate by 500 mg weekly; max 2000 mg/day divided twice daily; extended-release: 500 mg orally once daily, titrate by 500 mg weekly; max 2000 mg/day once daily.
Oral, 500 mg once daily, increase by 500 mg weekly to maximum 2000 mg once daily.
None Documented
None Documented
Terminal elimination half-life: 6.2 hours (range 4.0-8.7 h); prolonged in renal impairment (up to 17.6 h at CrCl <60 mL/min).
Terminal elimination half-life is approximately 6.2 hours in patients with normal renal function; prolonged to up to 17.6 hours in renal impairment (eGFR <30 mL/min).
Renal elimination of unchanged drug: 90%; fecal: 10% (biliary negligible).
Renal elimination of unchanged drug accounts for approximately 90% of an absorbed dose; fecal excretion is minimal (<5%).
Category C
Category C
Biguanide Antidiabetic
Biguanide Antidiabetic